Agenus Inc.

AGEN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Operating Activities
Net Income $-54.8M $-63.5M $-48.6M $-64.5M $-73.4M $-70.9M $-74.1M $-56.7M
Depreciation & Amortization $3.4M $3.4M $5.2M $2.9M $3.0M $2.6M $1.9M $1.7M
Depreciation — — — — — — — —
Amortization — — — — — — — —
Stock-Based Compensation $4.0M $4.2M $5.5M $5.9M $6.0M $5.5M $4.3M $4.5M
Net Cash from Operating Activities $-38.2M $-38.2M $-40.4M $-65.2M $-60.0M $-58.5M $-47.3M $-32.2M
Investing Activities
Capital Expenditures $461.0K $35.0K $223.0K $3.5M $4.4M $1.8M $14.3M $15.7M
Business Acquisitions — — — — — — $-735.0K $0
Net Cash from Investing Activities $-237.0K $229.0K $2.8M $11.5M $517.0K $-11.5M $-6.4M $-15.6M
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $79.1M $14.8M $7.3M $18.0M $38.3M $56.3M $23.8M $28.2M
Net Change in Cash $40.8M $-23.3M $-30.2M $-35.9M $-21.6M $-13.9M $-29.7M $-20.0M
Free Cash Flow $-38.6M $-38.2M $-40.6M $-68.7M $-64.5M $-60.4M $-61.7M $-47.9M
← Newer Page 2 of 8 Older →